DIACEUTICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 103 GBX | 0.00% |
|
-0.48% | +18.39% |
| Apr. 02 | Roadside shares suspended; Adnams looks for funds | AN |
| Mar. 21 | Diaceutics upgrades diagnositc commercialisation platform, DXRX | AN |
| Sales 2023 * | 23.89M 29.9M | Sales 2024 * | 29.61M 37.07M | Capitalization | 86.99M 109M |
|---|---|---|---|---|---|
| Net income 2023 * | -1M -1.25M | Net income 2024 * | -2M -2.5M | EV / Sales 2023 * | 2.97 x |
| Net cash position 2023 * | 16.13M 20.19M | Net cash position 2024 * | 13.48M 16.88M | EV / Sales 2024 * | 2.48 x |
| P/E ratio 2023 * |
-61
x | P/E ratio 2024 * |
-54.5
x | Employees | 151 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 65.46% |
More Fundamentals
* Assessed data
More news
Latest transcript on Diaceutics PLC
More press releases
| 1 week | -0.48% | ||
| Current month | -3.74% | ||
| 1 month | -0.96% | ||
| 3 months | +11.96% | ||
| 6 months | +17.05% | ||
| Current year | +18.39% |
1 week
102.00
104.00
1 month
102.00107.00
Current year
84.50107.00
1 year
79.00110.00
3 years
74.00131.50
5 years
74.00195.00
10 years
74.00195.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ryan Keeling
CEO | Chief Executive Officer | 40 | 08-05-31 |
Nick Roberts
DFI | Director of Finance/CFO | - | 22-03-17 |
Julie Browne
COO | Chief Operating Officer | - | 22-03-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Graham Paterson
BRD | Director/Board Member | - | 23-09-30 |
Deborah Davis
CHM | Chairman | 61 | 21-01-03 |
Peter Keeling
BRD | Director/Board Member | 63 | 04-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 103 | 0.00% | 1 941 |
| 24-04-25 | 103 | 0.00% | 5,041 |
| 24-04-24 | 103 | 0.00% | 14,948 |
| 24-04-23 | 103 | -0.48% | 66,366 |
| 24-04-22 | 103.5 | 0.00% | 7,298 |
Delayed Quote London S.E., April 26, 2024 at 05:02 am EDT
More quotes
Diaceutics PLC is a United Kingdom-based company, which is a provider of technology and solutions. The Company provides pharma and biotech companies with an end-to-end commercialization solution for precision medicine through data analytics, scientific and advisory services enabled by its platform DXRX - The Diagnostics Network. The Company operates through three segments: Insight Solutions (Data), Engagement Solutions (Tech enabled services), and Advisory Services (Professional services). The Companyâs DXRX - The Diagnostics Network is a diagnostic commercialization platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories. It provides unrivalled access to multiple pipelines of real-world diagnostic testing data from a global network of laboratories. Its Tech Enabled Services offers clinical testing labs to provide enablement and educational services in novel biomarkers.
Sector
Business Support Services
Calendar
2024-05-21
- Q4 2023 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.03
GBP
Average target price
1.666
GBP
Spread / Average Target
+61.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +18.39% | 109M | |
| +5.34% | 4.04B | |
| 0.00% | 1.97B | |
| +20.98% | 1.92B | |
| -8.89% | 1.61B | |
| +3.13% | 1.65B | |
| -20.72% | 1.51B | |
| -23.29% | 1.36B | |
| -10.70% | 1.13B | |
| -6.30% | 1.03B |
- Stock Market
- Equities
- DXRX Stock
